Сравнение
Icatibant vs. Bremelanotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
138614-30-9
189691-06-3
Молекулярная масса
1304.52 g/mol
1025.18 g/mol
Период полувыведения
нет данных
2.7 h
Последовательность
нет данных
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHМеханизм действия
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
5
из них на людях
1
5
Зафиксированные эффекты
1
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Icatibant and Bremelanotide?
- Icatibant is classified as "Исследования (прочее)", while Bremelanotide is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Icatibant or Bremelanotide?
- The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Icatibant and Bremelanotide in Germany and the United States?
- Германия: Icatibant — Рецептурный, Bremelanotide — Не одобрено. США: Icatibant — Рецептурный, Bremelanotide — Рецептурный. These are factual summaries with source and review date on the individual pages.